IP Library Granted Patent US 9,169,292
Granted Patent B2
US 9,169,292 · App. 13/771,305 · Granted Oct 27, 2015

Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof

Inventors: Grant Gallagher (Milltown, NJ); Raymond Yu (East Brunswick, NJ); Jonathan Brazaitis (Parlin, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
C07K7/08C07K14/001C07K14/54A61K38/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,169,292
App. No.
13/771,305
Granted
Oct 27, 2015
Kind
B2
Abstract

The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX 1 X 2 X 3 W, where W is tryptophan, and X 1 , X 2 and X 3 are amino acids, with the proviso that when one of X 1 , X 2 or X 3 is W, the remaining two of X 1 , X 2 or X 3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.

Claims (5)

1. An isolated polypeptide, wherein said isolated polypeptide inhibits the binding of IL-23 to IL-23 receptor and the IL-23-mediated signaling, and wherein said isolated polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, and SEQ ID NO: 166.

2. An isolated polypeptide of 9-18 amino acids in length, wherein said isolated polypeptide comprises a core structure that consists of the amino acid sequence of WVDYW (SEQ ID NO: 150) or WQDYW (SEQ ID NO: 151), wherein said isolated polypeptide inhibits the binding of IL-23 to IL-23 receptor and the IL-23-mediated signaling.

3. The isolated polypeptide of claim 2 , wherein said isolated polypeptide is selected from the group consisting of SEQ NO: 152, SEQ ID NO: 153, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 163, and SEQ ID NO: 164.

4. The isolated polypeptide of claim 2 , wherein said isolated polypeptide is a cyclic peptide through a disulfide bridge between two cysteine residues.

5. The isolated polypeptide of claim 2 , wherein said isolated polypeptide is 12 amino acids in length.

Assignments (5)
SECURITY INTEREST Recorded Jul 13, 2022
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 060638/0353 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: GALLAGHER, GRANT; YU, RAYMOND; BRAZAITIS, JONATHAN
To: MEDICAL DIAGNOSTIC LABORATORIES, LLC
Reel/Frame 036266/0274 →
Continuity (3)
Continuation In Part 13523286 · Jun 14, 2012
Provisional Application 61520710 · Jun 14, 2011
Related Publication 20130172272A1 · Jul 4, 2013